{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:15:40Z","timestamp":1782929740975,"version":"3.54.5"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Insufficient oral intake in advanced gastric cancer (AGC) limits the use of several drugs. We aimed to determine the oral intake status of patients with AGC during later-line chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>We retrospectively evaluated data of patients with AGC who experienced disease progression during first-line chemotherapy administered from January 2012 to December 2018 in a single institution. We defined \u201cinsufficient oral intake\u201d as requiring daily intravenous fluids or hyperalimentation. Multivariate logistic regression was performed to identify oral intake-related factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among 589 included patients, at disease progression during first-line, second-line, and third-line chemotherapy, 78.3% (461), 53.3% (314), and 30.4% (179) of patients, respectively, exhibited sufficient oral intake. Fourth-line chemotherapy was initiated for 22.2% (131) of patients, with 20.0% (118) exhibiting sufficient oral intake. During second-line and third-line chemotherapy, 11\/67 (16%) and 2\/39 (5%) patients, respectively, exhibited improvements in oral intake; 85\/428 (19.9%) and 70\/259 (27.0%), respectively, exhibited deteriorations in oral intake. Factors correlated to deterioration in oral intake during second-line chemotherapy were poor Eastern Cooperative Oncology Group Performance Status (odds ratio, 4.32; <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001), moderate or severe ascites (1.96; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.045), peritoneal metastasis (2.12; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.029), prior palliative surgery (3.41; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.003), and high neutrophil-to-lymphocyte ratio (3.09; <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001); those correlated to deterioration in oral intake during third-line chemotherapy were poorly differentiated pathology (2.52; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.025) and high neutrophil-to-lymphocyte ratio (2.65; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.006).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>As later-line chemotherapy is ineffective in improving oral intake in patients with AGC, careful adaptation of regimens is required for patients at risk for impaired oral intake.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000835","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T15:05:21Z","timestamp":1621868721000},"page":"388-394","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Clinical Impact of Oral Intake in Second-line or Third-line Chemotherapy for 589 Patients With Advanced Gastric Cancer"],"prefix":"10.1097","volume":"44","author":[{"given":"Takatsugu","family":"Ogata","sequence":"first","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiya","family":"Narita","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Kumanishi","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiko","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Kato","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nozawa","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Honda","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ando","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tajika","sequence":"additional","affiliation":[{"name":"Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[{"name":"Clinical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","article-title":"Japanese gastric cancer treatment guidelines 2018. 5th ed","volume":"24","year":"2021","journal-title":"Gastric Cancer"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00280-018-3569-9","article-title":"Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis","volume":"81","author":"Iizumi","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/jjco\/hyt114","article-title":"Randomized phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)","volume":"43","author":"Shirao","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"R5-20250527","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","article-title":"Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G)","volume":"23","author":"Nakajima","year":"2020","journal-title":"Gastric Cancer"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1186\/s12885-019-5720-3","article-title":"Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study","volume":"19","author":"Arai","year":"2019","journal-title":"BMC Cancer"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000320759","article-title":"Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat","volume":"79","author":"Shitara","year":"2010","journal-title":"Oncology"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1111\/ajco.13110","article-title":"Impact of modified FOLFOX-6 for patients with gastric cancer and a gastrointestinal obstruction","volume":"15","author":"Yukami","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.2147\/OTT.S184665","article-title":"Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake","volume":"11","author":"Osumi","year":"2018","journal-title":"Onco Targets Ther"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10147-010-0135-9","article-title":"Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study","volume":"16","author":"Iwasa","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10147-020-01684-z","article-title":"Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy","volume":"25","author":"Iwasa","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"R14-20250527","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s10120-017-0759-9","article-title":"Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer","volume":"21","author":"Makiyama","year":"2018","journal-title":"Gastric Cancer"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10120-016-0670-9","article-title":"Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes","volume":"20","author":"Nishimura","year":"2017","journal-title":"Gastric Cancer"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10120-017-0702-0","article-title":"Validation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials","volume":"20","author":"Takahari","year":"2017","journal-title":"Gastric Cancer"},{"key":"R18-20250527","first-page":"395","article-title":"Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer\u2212Pooled analysis from three multicenter, randomized, controlled trials using individual patient data","volume":"222","author":"Chau","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:08:24Z","timestamp":1748365704000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000835"}},"subtitle":["A Retrospective Cohort Study"],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000835","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,24]]}}}